What is Skin Analytics?
Skin Analytics is at the forefront of medical technology, utilizing its AI as a Medical Device (AIaMD) called DERM to revolutionize skin cancer pathways. The company's core mission is to democratize access to expert-level skin cancer assessments, thereby improving patient survival rates and delivering sustainable solutions for global health systems. By integrating advanced artificial intelligence, Skin Analytics aims to significantly reduce the economic impact of skin cancer, making high-quality diagnostic tools more accessible and efficient.
How much funding has Skin Analytics raised?
Skin Analytics has raised a total of $26.5M across 4 funding rounds:
Grant
$100K
Corporate Investment
$1.2M
Series A
$5.2M
Series B
$19.9M
Grant (2014): $100K with participation from Founder.org
Corporate Investment (2018): $1.2M led by Bristol Private Equity Club
Series A (2020): $5.2M supported by Mustard Seed Venture INC, Nesta Holding Co, and Hoxton Ventures
Series B (2025): $19.9M featuring Intrepid Partners
Key Investors in Skin Analytics
Hoxton Ventures
Hoxton Ventures is an early-stage venture capital firm based in London that invests in European technology startups with global scaling potential, focusing on disruptive or category-inventing companies. They typically invest between $500,000 and $5 million in pre-seed and seed-stage companies.
Intrepid Partners
Intrepid Partners specializes in project management and business consultancy services, primarily for the lease and loan industries, managing projects from inception to completion and offering consultancy on financial and regulatory matters.
Founder.org
FOUNDER.org is a startup investor and company-building program for young entrepreneurs, providing funding and an extensive program to help build high-impact companies with a focus on hypergrowth and solving major global problems.
What's next for Skin Analytics?
With the recent infusion of $19.9M in a major strategic investment, Skin Analytics is poised for accelerated expansion and technological advancement. This substantial backing, part of its $26.5M in total capital, suggests the company is entering a scaling phase, likely focusing on broadening its market reach, enhancing its AI capabilities, and forging deeper partnerships within the healthcare sector. The strategic nature of this investment indicates a strong belief in Skin Analytics' long-term vision and its potential to disrupt the dermatology diagnostics landscape.
See full Skin Analytics company page
